JMP Securities Reiterates Market Outperform Rating on Astria Therapeutics (ATXS)

February 18, 2025 4:12 AM EST Send to a Friend
JMP Securities analyst Jonathan Wolleben reiterated a Market Outperform rating and $26.00 price target on Astria Therapeutics (NASDAQ: ATXS).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login